Atnaujinkite slapukų nuostatas

El. knyga: Prostate Cancer: A Multidisciplinary Approach to Diagnosis and Management

Edited by , Series edited by , Edited by , Edited by , Edited by

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.

The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life.

A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.

Key Features:

Delineates a practical, concise approach to multidisciplinary management of prostate cancer Provides a wide range of perspectives and expertise Written and edited by an international, multidisciplinary team of prostate cancer specialists Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life Includes discussion of important emerging topics such as gene profiling and targeting therapies and comparative effectiveness data
Contributors xi
Series Foreword xvii
Preface xix
Acknowledgments xxi
I Epidemiology, Screening, and Diagnosis
1 Introduction: The Multidisciplinary Approach to Prostate Cancer
3(64)
Leonard G. Gomella
2.1 Epidemiology of Prostate Cancer
11(14)
Kathryn M. Wilson
Lorelei A. Mucci
2.2 Diet and Prostate Cancer
25(8)
James R. Marshall
2.3 Epidemiology: Obesity as a Risk Factor
33(20)
Emma H. Allott
Stephen J. Freedland
3.1.1 Screening and Diagnosis: The Pros of PSA Screening
37(6)
Janine L. Oliver
Gurdarshan S. Sandhu
Gerald L. Andriole
Robert L. Grubb
3.1.2 The Argument Against Prostate Cancer Screening
43(6)
Otis W. Brawley
3.1.3 How Do We Improve PSA Accuracy?
49(4)
Toru Sugihara
Michael W. Kattan
3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies
53(6)
Ibrahim Kulac
Angelo M. DeMarzo
3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging
59(8)
Dima Raskolnikov
Baris Turkbey
Liza Lindenberg
Peter L. Choyke
Peter A. Pinto
4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift
67(48)
Chad A. Reichard
Eric A. Klein
5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging
77(8)
Heesun Shin
Ismael A. Vergara
Anirban P. Mitra
Timothy J. Triche
Elai Davicioni
5.2 Genomics and Risk Assessment
85(8)
Hao G. Nguyen
Matthew R. Cooperberg
Peter R. Carroll
5.3 Future Direction: Novel Urine and Serum Markers
93(4)
Waleed A. Hassen
5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging
97(18)
Michael J. Donovan
Faisal M. Khan
Richard Scott
Gerardo Fernandez
Carlos Cordon-Cardo
5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer
101(5)
Mathew L. Thakur
Edouard J. Trabulsi
Sung M. Kim
Charles M. Intenzo
Leonard G. Gomella
5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging
106(3)
Victor Sai
Antonio C. Westphalen
5.5.3 Future Direction: Contrast Ultrasound
109(6)
Sanjay Kasturi
Edouard J. Trabulsi
Ethan J. Halpern
6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer
115(10)
Jonathan L. Silberstein
James A. Eastham
II Treatment for Low-Risk, Localized Disease
7 Active Surveillance for Prostate Cancer: An Overview
125(8)
Laurence Klotz
8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet
133(114)
Jillian Scambia
Annie Darves-Bornoz
Aaron Katz
9.1 Traditional Radical Prostatectomy
143(6)
Zachary L. Smith
Thomas J. Guzzo
9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications
149(12)
Fernando Pablo Secin
Karim Touijer
9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience
161(4)
Costas D. Lallas
Edouard J. Trabulsi
9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy
165(36)
Costas D. Lallas
10.1.1 External Beam Radiation Therapy: Conventional Fractionation
169(10)
David E. Greene
Richard K. Valicenti
10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer
179(9)
Nicholas G. Zaorsky
Robert B. Den
10.1.3 Stereotactic Body Radiation Therapy for Localized Prostate Cancer
188(8)
Nicholas G. Zaorsky
Robert B. Den
10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy
196(5)
Phillip J. Gray
Ayal A. Aizer
Jason A. Efstathiou
10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy
201(6)
Peter Grimm
11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies
207(8)
Joshua A. Cohn
Aytekin Oto
Scott E. Eggener
11.2 Hyperthermia for Prostate Cancer
215(4)
Mark Hurwitz
11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy
219(4)
Ashley G. Winter
Jonathan A. Coleman
11.4 Laser Ablative Techniques for Prostate Cancer
223(4)
Ashley G. Winter
Jonathan A. Coleman
11.5 Irreversible Electroporation (IRE) Prostate Ablation
227(4)
Ashley G. Winter
Jonathan A. Coleman
12.1 Quality of Life With Surgery
231(4)
Alana M. Murphy
Patrick J. Shenot
12.2 Quality of Life With Androgen Deprivation Therapy
235(4)
Alana M. Murphy
Patrick J. Shenot
12.3 Quality of Life With External Beam Radiation Therapy
239(4)
Steve K. Williams
Sameer Chopra
Farhang Rabbani
12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer
243(4)
Steve K. Williams
Farhang Rabbani
13 Role for Comparative Effectiveness Research in Treatment Decision Making
247(12)
Ryan T. Jones
Mark V. Mishra
Timothy N. Showalter
14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond
259(10)
Nicholas G. Zaorsky
Robert B. Den
Jianqing Lin
15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate Cancer-Specific Mortality
269(8)
Peter Orio
Nathan Bittner
III Treatment for High-Risk, Localized, and Locally Advanced Disease
16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy
277(8)
Thomas J. Pugh
IV Treatment of Disseminated Disease
17 Salvage Therapy for Rising PSA
285(14)
Judd W. Moul
18 Metastatic Hormone Sensitive Prostate Cancer
299(102)
Jean Hoffman-Censits
William Kevin Kelly
19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape
311(12)
Susan F. Slovin
19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms
323(14)
Abdel Hai Alqwasmi
Nicholas G. Zaorsky
Ulka Vaishampayan
19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors
337(28)
Austin Poole
Ajjai Alva
Julia Batten
Neeraj Agarwal
19.4.1 Radiation and the Immune System
347(7)
Andrew Sharabi
Charles Drake
19.4.2 Immunotherapy: Agents Targeting Prostate Cancer
354(11)
Gurveen Kaur
Naveed H. Akhtar
Beerinder K. Singh
Scott T. Tagawa
19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption
365(12)
Clara Hwang
Elisabeth I. Heath
19.6 Treatment of Bone Metastases: Radiopharmaceuticals
377(10)
Hossein Jadvar
Leslie Ballas
David I. Quinn
19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer
387(14)
Alan D. Smith
Joaquin Mateo
Johann S. de Bono
Index 401
Adam P. Dicker MD

William Kevin Kelly MD

Edouard J. Trabulsi MD

Nicholas G. Zaorsky MD